VEGFA and cholangiocarcinoma: Furthermore, cholangiocarcinoma releases the exosomal miR-182/183-5p into bile, targeting hydroxyprostaglandin dehydrogenase in both cholangiocarcinoma and mast cells, leading to an increased release of prostaglandin E2 and VEGF-A.